{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,5]],"date-time":"2026-04-05T08:40:27Z","timestamp":1775378427962,"version":"3.50.1"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["GNT1194694"],"award-info":[{"award-number":["GNT1194694"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP2008625"],"award-info":[{"award-number":["APP2008625"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.rmed.2025.108042","type":"journal-article","created":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T16:16:35Z","timestamp":1741968995000},"page":"108042","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Relationship between sputum bacterial load and lung function in children with cystic fibrosis receiving tobramycin"],"prefix":"10.1016","volume":"240","author":[{"given":"Kiera","family":"Harwood","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6545-9408","authenticated-orcid":false,"given":"Stephen","family":"Duffull","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9761-0072","authenticated-orcid":false,"given":"Tony","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2404-4830","authenticated-orcid":false,"given":"Alice","family":"Lei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9505-5498","authenticated-orcid":false,"given":"Sarah","family":"Manning","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3883-2163","authenticated-orcid":false,"given":"Casey","family":"Pell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarath","family":"Ranganathan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phil","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geraint","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Indy","family":"Sandaradura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3164-8849","authenticated-orcid":false,"given":"Catherine","family":"Satzke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shivanthan","family":"Shanthikumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Gwee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.rmed.2025.108042_bib1","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/ppul.10127","article-title":"Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis","volume":"34","author":"Emerson","year":"2002","journal-title":"Pediatr. Pulmonol."},{"issue":"5","key":"10.1016\/j.rmed.2025.108042_bib2","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1164\/rccm.200909-1421OC","article-title":"Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation","volume":"182","author":"Sanders","year":"2010","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"10","key":"10.1016\/j.rmed.2025.108042_bib3","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1056\/NEJM199409083311003","article-title":"Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group","volume":"331","author":"Fuchs","year":"1994","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.rmed.2025.108042_bib4","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1164\/rccm.200812-1845PP","article-title":"Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations","volume":"180","author":"Flume","year":"2009","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"2","key":"10.1016\/j.rmed.2025.108042_bib5","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.jpeds.2005.10.019","article-title":"Cystic fibrosis pulmonary exacerbations","volume":"148","author":"Ferkol","year":"2006","journal-title":"J. Pediatr."},{"issue":"3","key":"10.1016\/j.rmed.2025.108042_bib6","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/MCP.0b013e32835f1afc","article-title":"Respiratory bacterial infections in cystic fibrosis","volume":"19","author":"Ciofu","year":"2013","journal-title":"Curr. Opin. Pulm. Med."},{"key":"10.1016\/j.rmed.2025.108042_bib7","series-title":"The Australian Cystic Fibrosis Data Registry Annual Report, 2017","author":"Ruseckaite","year":"2019"},{"key":"10.1016\/j.rmed.2025.108042_bib8","series-title":"On Behalf of the Australian Cystic Fibrosis Data Registry, the Australian Cystic Fibrosis Data Registry Annual Report, 2022","author":"Ahern","year":"2023"},{"issue":"2","key":"10.1016\/j.rmed.2025.108042_bib9","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01953-2017","article-title":"The independent contribution of Pseudomonas aeruginosa infection to long-term clinical outcomes in bronchiectasis","volume":"51","author":"Ara\u00fajo","year":"2018","journal-title":"Eur. Respir. J."},{"issue":"6","key":"10.1016\/j.rmed.2025.108042_bib10","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1164\/ajrccm.162.6.2005018","article-title":"Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with multiresistant strains of Pseudomonas aeruginosa","volume":"162","author":"Lang","year":"2000","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"4","key":"10.1016\/j.rmed.2025.108042_bib11","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02055-17","article-title":"Optimization of a meropenem-tobramycin combination dosage regimen against hypermutable and nonhypermutable Pseudomonas aeruginosa via mechanism-based modeling and the hollow-fiber infection model","volume":"62","author":"Landersdorfer","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"10.1016\/j.rmed.2025.108042_bib12","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.diagmicrobio.2005.02.011","article-title":"Pharmacodynamics of tobramycin in patients with cystic fibrosis","volume":"52","author":"Mouton","year":"2005","journal-title":"Diagn. Microbiol. Infect. Dis."},{"issue":"4","key":"10.1016\/j.rmed.2025.108042_bib13","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1093\/jac\/dkl328","article-title":"Once-daily tobramycin in cystic fibrosis: better for clinical outcome than thrice-daily tobramycin but more resistance development?","volume":"58","author":"Burkhardt","year":"2006","journal-title":"J. Antimicrob. Chemother."},{"issue":"12","key":"10.1016\/j.rmed.2025.108042_bib14","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1002\/phar.2193","article-title":"Reappraisal of contemporary pharmacokinetic and pharmacodynamic principles for informing aminoglycoside dosing","volume":"38","author":"Bland","year":"2018","journal-title":"Pharmacotherapy"},{"issue":"4","key":"10.1016\/j.rmed.2025.108042_bib15","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/j.1365-2125.2007.03045.x","article-title":"Target concentration intervention is needed for tobramycin dosing in paediatric patients with cystic fibrosis--a population pharmacokinetic study","volume":"65","author":"Hennig","year":"2008","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"5","key":"10.1016\/j.rmed.2025.108042_bib16","doi-asserted-by":"crossref","DOI":"10.1128\/aac.02377-21","article-title":"A pharmacokinetic analysis of tobramycin in patients less than five years of age with cystic fibrosis: assessment of target attainment with extended-interval dosing through simulation","volume":"66","author":"Downes","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.rmed.2025.108042_bib17","doi-asserted-by":"crossref","first-page":"63","DOI":"10.5863\/1551-6776-28.1.63","article-title":"Review of tobramycin dosing in pediatric patients with cystic fibrosis","volume":"28","author":"Imburgia","year":"2023","journal-title":"J. Pediatr. Pharmacol. Therapeut."},{"issue":"12","key":"10.1016\/j.rmed.2025.108042_bib18","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1002\/ppul.25037","article-title":"Area under the curve achievement of once daily tobramycin in children with cystic fibrosis during clinical care","volume":"55","author":"Brockmeyer","year":"2020","journal-title":"Pediatr. Pulmonol."},{"issue":"11","key":"10.1016\/j.rmed.2025.108042_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0079010","article-title":"Is the improvement of CF patients, hospitalized for pulmonary exacerbation, correlated to a decrease in bacterial load?","volume":"8","author":"Deschaght","year":"2013","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.rmed.2025.108042_bib20","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jcf.2011.05.002","article-title":"Does bacterial density in cystic fibrosis sputum increase prior to pulmonary exacerbation?","volume":"10","author":"Stressmann","year":"2011","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.rmed.2025.108042_bib21","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s12879-015-0856-5","article-title":"Reduction in Pseudomonas aeruginosa sputum density during a cystic fibrosis pulmonary exacerbation does not predict clinical response","volume":"15","author":"Lam","year":"2015","journal-title":"BMC Infect. Dis."},{"issue":"10","key":"10.1016\/j.rmed.2025.108042_bib22","doi-asserted-by":"crossref","DOI":"10.1172\/JCI167957","article-title":"Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persist","volume":"133","author":"Nichols","year":"2023","journal-title":"J. Clin. Investig."},{"issue":"155","key":"10.1016\/j.rmed.2025.108042_bib23","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0112-2019","article-title":"Impact of CFTR modulator use on outcomes in people with severe cystic fibrosis lung disease","volume":"29","author":"Shteinberg","year":"2020","journal-title":"Eur. Respir. Rev."},{"issue":"4","key":"10.1016\/j.rmed.2025.108042_bib24","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jcf.2012.02.005","article-title":"Multiple antibiotic-resistant Pseudomonas aeruginosa and lung function decline in patients with cystic fibrosis","volume":"11","author":"Ren","year":"2012","journal-title":"J. Cyst. Fibros."},{"issue":"1","key":"10.1016\/j.rmed.2025.108042_bib25","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1159\/000087686","article-title":"Outcomes of adults with cystic fibrosis infected with antibiotic-resistant Pseudomonas aeruginosa","volume":"73","author":"Lechtzin","year":"2006","journal-title":"Respiration"},{"issue":"11","key":"10.1016\/j.rmed.2025.108042_bib26","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1136\/thoraxjnl-2018-211510","article-title":"Sputum microbiota is predictive of long-term clinical outcomes in young adults with cystic fibrosis","volume":"73","author":"Acosta","year":"2018","journal-title":"Thorax"},{"key":"10.1016\/j.rmed.2025.108042_bib27","series-title":"Medication Guideline: Tobramycin in Cystic Fibrosis","author":"Shanthikumar","year":"2023"},{"key":"10.1016\/j.rmed.2025.108042_bib28","article-title":"Aminoglycoside dosing and monitoring: CHW practice guideline v6","year":"2021","journal-title":"The Children\u2019s Hospital at Westmead"},{"issue":"6","key":"10.1016\/j.rmed.2025.108042_bib29","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.jcf.2020.03.008","article-title":"Total bacterial load, inflammation, and structural lung disease in paediatric cystic fibrosis","volume":"19","author":"Taylor","year":"2020","journal-title":"J. Cyst. Fibros."},{"issue":"8","key":"10.1016\/j.rmed.2025.108042_bib30","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1016\/j.celrep.2019.01.091","article-title":"Human and extracellular DNA depletion for metagenomic analysis of complex clinical infection samples yields optimized viable microbiome profiles","volume":"26","author":"Nelson","year":"2019","journal-title":"Cell Rep."},{"issue":"8","key":"10.1016\/j.rmed.2025.108042_bib31","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.meegid.2010.08.008","article-title":"Direct detection of Pseudomonas aeruginosa from patients with healthcare associated pneumonia by real time PCR","volume":"10","author":"Feizabadi","year":"2010","journal-title":"Infect. Genet. Evol."},{"key":"10.1016\/j.rmed.2025.108042_bib32","series-title":"Performance Standards for Antimicrobial Susceptibility Testing","year":"2023"},{"issue":"8","key":"10.1016\/j.rmed.2025.108042_bib33","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1136\/thx.2011.161117","article-title":"Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis","volume":"66","author":"Boer","year":"2011","journal-title":"Thorax"},{"issue":"1","key":"10.1016\/j.rmed.2025.108042_bib34","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1378\/chest.121.1.64","article-title":"Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis","volume":"121","author":"Britto","year":"2002","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.rmed.2025.108042_bib35","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1055\/s-0039-1697975","article-title":"Acute pulmonary exacerbations in cystic fibrosis","volume":"40","author":"Goss","year":"2019","journal-title":"Semin. Respir. Crit. Care Med."},{"issue":"4 Pt 1","key":"10.1016\/j.rmed.2025.108042_bib36","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1164\/ajrccm\/141.4_Pt_1.914","article-title":"Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone","volume":"141","author":"Regelmann","year":"1990","journal-title":"Am. Rev. Respir. Dis."},{"issue":"4","key":"10.1016\/j.rmed.2025.108042_bib37","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0022-3476(88)80165-3","article-title":"Sputum changes associated with therapy for endobronchial exacerbation in cystic fibrosis","volume":"112","author":"Smith","year":"1988","journal-title":"J. Pediatr."},{"issue":"1","key":"10.1016\/j.rmed.2025.108042_bib38","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s40168-020-00810-3","article-title":"Lung function and microbiota diversity in cystic fibrosis","volume":"8","author":"Cuthbertson","year":"2020","journal-title":"Microbiome"},{"issue":"6","key":"10.1016\/j.rmed.2025.108042_bib39","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/ppul.21221","article-title":"Pulmonary exacerbations in cystic fibrosis with negative bacterial cultures","volume":"45","author":"Zemanick","year":"2010","journal-title":"Pediatr. Pulmonol."},{"issue":"2","key":"10.1016\/j.rmed.2025.108042_bib40","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1183\/09031936.00202311","article-title":"Viral infections trigger exacerbations of cystic fibrosis in adults and children","volume":"40","author":"Wark","year":"2012","journal-title":"Eur. Respir. J."},{"issue":"6","key":"10.1016\/j.rmed.2025.108042_bib41","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jcf.2018.09.006","article-title":"Attenuation of exacerbation","volume":"17","author":"Ranganathan","year":"2018","journal-title":"J. Cyst. Fibros."},{"issue":"2","key":"10.1016\/j.rmed.2025.108042_bib42","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jcf.2022.11.001","article-title":"Clinical outcomes associated with Achromobacter species infection in people with cystic fibrosis","volume":"22","author":"Kerem","year":"2023","journal-title":"J. Cyst. Fibros."},{"issue":"2","key":"10.1016\/j.rmed.2025.108042_bib43","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00076-2021","article-title":"Achromobacter xylosoxidans airway infection is associated with lung disease severity in children with cystic fibrosis","volume":"7","author":"Marsac","year":"2021","journal-title":"ERJ Open Res"},{"issue":"S3","key":"10.1016\/j.rmed.2025.108042_bib44","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1002\/ppul.24157","article-title":"Rapid therapeutic advances in CFTR modulator science","volume":"53","author":"Clancy","year":"2018","journal-title":"Pediatr. Pulmonol."},{"issue":"7","key":"10.1016\/j.rmed.2025.108042_bib45","doi-asserted-by":"crossref","DOI":"10.3390\/cells11071243","article-title":"CFTR modulator therapies: potential impact on airway infections in cystic fibrosis","volume":"11","author":"Saluzzo","year":"2022","journal-title":"Cells"},{"issue":"12","key":"10.1016\/j.rmed.2025.108042_bib46","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1164\/rccm.201609-1954OC","article-title":"Restoring cystic fibrosis transmembrane conductance regulator function reduces airway bacteria and inflammation in people with cystic fibrosis and chronic lung infections","volume":"195","author":"Hisert","year":"2017","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"2","key":"10.1016\/j.rmed.2025.108042_bib47","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02153-2022","article-title":"Longitudinal effects of elexacaftor\/tezacaftor\/ivacaftor on sputum viscoelastic properties, airway infection and inflammation in patients with cystic fibrosis","volume":"62","author":"Schaupp","year":"2023","journal-title":"Eur. Respir. J."},{"issue":"4","key":"10.1016\/j.rmed.2025.108042_bib48","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1136\/thx.2006.060889","article-title":"Exacerbations in cystic fibrosis. 1: epidemiology and pathogenesis","volume":"62","author":"Goss","year":"2007","journal-title":"Thorax"}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611125001040?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611125001040?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T22:44:53Z","timestamp":1744325093000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611125001040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":48,"alternative-id":["S0954611125001040"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2025.108042","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Relationship between sputum bacterial load and lung function in children with cystic fibrosis receiving tobramycin","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2025.108042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108042"}}